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Background. Recently, NICE guidelines recommend the use of computed tomographic angiography (CTA) as the first line of
investigation for new onset chest pain. We sought to evaluate the impact of the integration of CTA in the diagnostic workup,
as either a first- or second-line of investigation, in the clinical practice for patients presenting with new onset chest pain, with
suspicion that it may be due to coronary artery disease (CAD).Method and Results. From 2014 to 2016, 208 outpatients (mean age
63.8 ± 12.7, 37% female) with an unknown CAD diagnosis were evaluated. About half (n=106, 51%) received usual testing care plus
CTA as a second-line investigation (group A), while the other half (n=102, 49%) received CTA as a first-line investigation (group
B). Care decisions and test interpretations were made by the attending physician. Obstructive CAD (O-CAD) was defined as >50%
stenosis in the principal branch. As determined by CTA, the rates of CAD in group A vs. group B were the following (P=0.001):
31.1% vs. 27.4% for normal/minimal CAD; 42.5% vs. 63.7% for no O-CAD; and 26.4% vs. 8.8% with O-CAD. Based on a diagnostic
result of no O-CAD, invasive angiography was cancelled in 42.6% (n=45) of group A patients, and additional functional tests were
cancelled for the same reason in 63.7% (n=65) of group B patients, without adverse events at median 3-year.The average diagnostic
cost for patients in our study was lower in group B (206 vs. 324.42 euro; P<0.0001). Conclusions. In clinical practice, CTA, as a
first- or second-line investigation, most commonly detected no O-CAD in new onset chest pain patients, leading us to safely avoid
unnecessary ICA or additional functional tests. The use of CTA as a first-line investigation also appears to be cost saving, but its
cost-effectiveness remains to be demonstrated in larger studies.
1. Introduction
For patients with suspected coronary artery disease (CAD),
inmany centers, the routine noninvasive diagnostic approach
consists of stress testing, with the applied test modality
depending on pretest probability, patient characteristics, local
availability, and expertise. The exercise ECG is the most
widely available and least expensive functional test, but it has
a modest diagnostic performance. Conversely, the negative
predictive value and the ability to exclude CAD are high for
computed tomographic angiography (CTA) [1, 2]. However,
CTA has a tendency to overestimate both the angiographic
and hemodynamic severity of CAD, producing results which
may necessitate further functional testing or ICA. Because
the prevalence of obstructive-CAD (O-CAD) is low in real-
world populations with stable chest pain symptoms [3],
CTA could be an efficient and cost-effective first-line test.
Recently, the PROMISE [4] and SCOT-HEART [5] studies
have suggested that an evaluation strategy based on coronary
CTA improves diagnostic certainty, as well as the efficiency
of triage to invasive catheterization. It also may reduce
radiation exposure when compared with functional stress
testing, with similar rates of cardiac events. Moreover, the
EVINCI [6] trial supports the use ofCTA for stable chest pain,
highlighting better performance in comparison with other
imaging strategies. Following the publication of these studies,
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the National Institute for Health and Care Excellence (NICE)
[7] recommended CTA as the first-line investigation for all
patients presenting with chest pain due to suspected CAD.
In the present prospective registry, we sought to evaluate the
impact of the integration of CTA as a first- or second-line
investigation in the diagnostic workup for the evaluation of
outpatients presenting with stable chest pain in our tertiary
center.
2. Material and Methods
From May 2014 to February 2016, 334 consecutive symp-
tomatic outpatients of age ≥18 years old, with new onset
chest pain, were referred to our Cardiovascular andThoracic
Department of Careggi Hospital (Florence, Italy) for the sus-
picion of CAD. Exclusion criteria for the prospective registry
were previously documented CAD (n=113), acute coronary
syndrome or clinical instability (n=5), contraindications to
CTA (n=2), and the need for emergent or urgent procedure
(n=1). Additional exclusion criteria included recent cardio-
vascular testing (<90 days; n=5). Thus, 208 outpatients pre-
senting with a low to intermediate likelihood of obstructive
CAD were enrolled in this registry to evaluate the impact of
integration of CTA in the diagnostic workup, using CTA as
either a first- or second-line of investigation. Patients were
enrolled by the attending physician, who, according to his
behavior—and without any restriction—chose the patient’s
diagnostic workup, generating two groups of patients. Specif-
ically, one group of patients receiving usual care testing (a
symptom-limited exercise test, an echo stress test, or SPECT)
according to the standard diagnostic workup, plus CTA as
a second-line investigation, irrespective of the functional
testing results, was classified as group A. Instead, patients
receiving CTA as a first-line investigation were classified as
group B (Figure 1). Care decisions and test interpretations
were made by the attending physician, without any con-
ditioning. All patients underwent CTA with a dual-source
CTA scanner (52% with high-pitch mode, depending on
the baseline heart rate), and followed scanning protocols
satisfying Society of Cardiac Computed Tomography quality
standards [8]. Normal/minimal CAD was defined as <30%
stenosis in principal branches of the left or right coronary
artery by visual estimate, while no O-CAD and O-CAD
were defined as ≥30-50% and >50% stenosis, respectively.
All subjects provided informed written consent, which was
approved by the local ethics committee. At least 3 authors
(N.C., M.B., and G.T.) had access to all data presented.
All authors are responsible for the data integrity. Follow-
up information for the occurrence of death, myocardial
infarction, or hospitalization for coronary angioplasty was
obtained by clinical visits or telephone interviews over the
course of the following 3 years. Hospital records of all patients
were screened for the occurrence of clinical events to confirm
the obtained information.
2.1. CTA Scan Protocol. All CTAs were performed using a
128-slice dual-source CTA system (SOMATOM Definition
Flash, Siemens Healthineers, Forchheim, Germany). The
detector collimation was 2×64×0.6 mm, and a flying focal
spot technique and a gantry rotation time of 280 msec were
used. Both tubes were operated at 100 or 120 kV, depending
on the bodymass index of the patient. Scout-based automatic
tube current modulation (Care Dose 4D, Siemens healthcare,
Forchheim, Germany) was used, with the reference tube
current-time product set at 320 mAs per rotation. The pitch
was 3.4 for flash CTA mode. Oral and/or intravenous beta-
blockers or oral ivabradine were administered if necessary, in
an attempt to achieve a target heart rate <60 beats/min. All
patients received sublingual nitrates. The contrast medium
(Iomeron 400, Bracco Altana Pharma, Konstanz, Germany)
and saline chaser were administered at 5 mL/s using a dual-
head power injector (Empower, ACIST) into an antecubital
vein, through an 18-gauge catheter. The patient’s heart rate
and ECG trace were recorded during examination. A test
bolus scan was performed to determine the transit time. An
injection of 15mL of iodinated contrastmediumwas followed
by a 30mL saline chaser.The time until the peak opacification
in the proximal ascending aorta was measured, and this time,
plus 2 for standard protocol, or plus 5 for high-pitch protocol,
was considered to represent the transit time of contrast agent.
Sixty-five milliliters of contrast medium, followed by a 50 mL
saline chaser, was administered, with bolus tracking using
a region of interest (ROI) in the ascending aorta. The scan
was automatically triggered when the tracking ROI reached
a threshold of 100 Hounsfield units (HU) above baseline
attenuation. In the flash mode (high-pitch spiral mode),
prospective ECG-triggering was used to obtain a complete
dataset in a single heartbeat starting at 60% of the R-R
interval. In the sequential mode (Spiral technique), the centre
of the data acquisition window was set at 70% of the R-R
interval. The entire heart was covered in three or four heart-
beats in a step-and-shoot fashion [9].
2.2. Image Reconstruction and Evaluation. Datasets for coro-
nary arteries were reconstructed with a slice thickness of 0.6
mm, an increment of 0.4 mm, a field of view of 180 mm,
a medium-soft convolution kernel (B26), and, in patients
exhibiting coronary calcium, an additional sharp convolution
kernel (B46). All reconstructed images were transferred to a
dedicated workstation (MMWP, Siemens Healthcare, Forch-
heim, Germany). Axial images, multiplanar reformations,
and maximum intensity projections were used to evaluate
arteries. Coronary artery segments were classified according
to a modified American Heart Association [10] protocol.
Segments were evaluated if the luminal diameter met or
exceeded 1.5 mm, as judged by two independent observers
(N.C. andM.A., eachwithmore than 9 years of coronaryCTA
experience). Any discordance in the interpretationwas solved
by a third observer (M.M. with more than 7 years reading
experience). Image quality was assessed semiquantitatively
using a four-point grading scale: (1) excellent (no artifacts,
unrestricted evaluation), (2) good (minor artifacts, good
diagnostic quality), (3) adequate (moderate artifacts, still
acceptable and diagnostic), and (4) not assessable (severe
artifacts impairing accurate evaluation). Images with a score
of 1–3 were considered acceptable for diagnosis [8].
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Figure 1: Study design flow diagram. CAD: coronary artery disease; CTA: computed tomographic angiography.
2.3. Radiation Dose Estimates. The radiation dose was
reported as dose-length product (DLP) and effective dose
(ED). For each patient, the ED was calculated using the
formula DLP x 0.014, using the 0.014 conversion factor for
chest radiation (in mSv/Gy/cm) [11].
2.4. Statistical Analysis. All variables are expressed as mean
value ± SD or medians with interquartile ranges (25th
to 75th percentile). Differences in patient characteristics,
radiation dose, and image quality were compared using
an independent-sample t-test (if normally distributed) or
Mann-Whitney U-test (if not) for continuous variables, using
𝜒
2 or Fisher’s exact test for categorical variables and the
Kruskal-Wallis test for nonparametric data, as appropriate.
The interrater agreement between the two observers in
assessing image quality was calculated using Cohen’s kappa
statistics. Kappa results were interpreted as being either
poor (𝜅 < 0.20), fair (𝜅=0.21–0.40), moderate (𝜅=0.41–0.60),
good (𝜅=0.61–0.80), very good (𝜅=0.81–0.90), or excellent
(𝜅 ≥0.91). For economic analysis, unadjusted diagnostic costs
were compared between the diagnostic strategies deployed
by groups A and B using the nonparametric Wilcoxon rank
sum test on all patients. For this economic analysis, the cost
for the exercise test is 113.5 euros, the echo stress test is 181
euros, SPECT is 433 euros, and the CT scan is 206 euros.
Statistical analyses were performed using commercially avail-
able software (SPSS, version 19.0, Chicago, IL, USA). A two-
sided p-value of less than 0.05 was considered statistically
significant.
3. Results
The 208 patients in the registry averaged 63.8 ± 12.7 years
of age, and 37% were women. The clinical characteristics
of the patients were similar, but group B (n=102, 49%)
was older and the rate of female gender was higher in
comparison with group A (n=106, 51%). All patients showed
an intermediate risk profile (see Table 1). Among the patients
in group A, 102 (96%) underwent symptom-limited exercise
electrocardiography with the standard Bruce protocol, 3 (3%)
underwent an echo stress test, and 1 (1%) was tested by
SPECT. According to the results of the usual care strategy,
group A patients were classified as exhibiting a negative
(n=54, 50.9%), inconclusive (n=44, 41.5%), or positive (n=8,
7.5%) result of the functional test. Based on the results of
CTA, as per patient analysis, the overall rate of patients
with no O-CAD (52.8%) was the highest when compared
to the rates of minimal/normal coronary artery (29.3%) and
O-CAD (17.7%). Specifically, in group A, the percentage of
normal/minimal lesion of coronary artery was 31.1% vs. 27.4%
in group B; the percentage of no significant O-CAD was
42.5% in group A vs. 63.7% in group B; and the percentage of
O-CAD was 26.4% in group A vs. 8.8% in group B (P=0.001)
(Table 2). Per vessel analysis, the number of diseased coronary
vessels was not significantly different in group A vs. group B
patients (Table 2). Moreover, in patients with coronary risk
factor (RF) ≥2 compared with patients with a coronary RF
of 0-1, the number of diseased coronary vessels (P=0.0035)
(Figure 2A), as well as the number of patients with proximal
plaques (P=0.0009) (Figure 3A), was higher. Additionally, the
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Table 1: Baseline clinical characteristics of the study population.
All Group A Group B p-value
(n=208) (n= 106) (n= 102)
Mean age (years) 63.8±12.7 61.5±12.5 66.17±12.7 0.008
Male gender, n (%) 131 (63%) 77 (72.7%) 54 (52.9%) 0.004
Obesity, n (%) 8 (3.8%) 3 (2.8%) 5 (4.9%) 0.492
Hypertension, n (%) 114 (54.8%) 54 (50.9%) 60 (58.9%) 0.267
Hypercholesterolemia, n (%) 67 (32.2%) 39 (36.8%) 28 (27.4%) 0.181
Diabetes mellitus, n (%) 33 (15.9%) 21 (19.8%) 12 (11.8%) 0.130
Smoking habits, n (%) 45 (21.6%) 18 (17.0%) 27 (26.4%) 0.129
Family history of CAD, n (%) 57 (27.4%) 31 (29.2%) 26 (25.5%) 0.641
Pretest probability 55.97±30.92 55.33±22.05 56.73±21.42 0.692
Data are presented as the mean±SD or as number (percentage) of patients; CAD: coronary artery disease; hypercholesterolemia: total cholesterol >5 mmol/L,
low-density lipoprotein >3 mmol/L, or on lipid-lowering medication.
Table 2: CTA angiographic characteristics by groups.
Group A Group B p-value
(n = 106) (n = 102)
Analysis by patient
No lesions or minimal lesions, n (%) 33 (31.1) 28 (27.4) 0.001
No obstructive lesions, n (%) 45 (42.6) 65 (63.7)
Obstructive lesions, n (%) 28 (26.4) 9 (8.8)
1 vessel, n (%) 10 (9.4) 18 (17.6) 0.369
2 vessels, n (%) 15 (14.1) 14 (13.7)
3 vessels, n (%) 11 (10.4) 8 (7.8)
Left main, n (%) 38 (35.8) 34 (33.3)
Analysis by segment
No lesions or minimal lesions, median (IQR) 0 (0-0) 0 (0-0) 0.164
Non obstructive lesions, median (IQR) 0 (0-3) 2 (0-4) 0.003
Obstructive lesions, median (IQR) 0 (0-1) 0 (0-0) 0.001
Analysis by plaque
Noncalcified plaques, median (IQR) 0 (0-0) 0 (0-0) 0.015
Partially calcified plaques, median (IQR) 0 (0-3) 1 (0-2) 0.870
Calcified plaques, median (IQR) 0 (0-1) 0 (0-1) 0.296
Data are presented as number (%) or median (IQR: interquartile range).
number of diseased coronary vessels (P=0.0199) (Figure 2B),
as well as the number of patients with proximal plaques
(P=0.0173) (Figure 3B), was higher in patients with an
intermediate or high tertile risk profile in comparison to
patients with a low tertile risk. Per segment analysis, in
group B patients, when compared with group A patients,
the number of segments showing no obstructive plaques
was higher (P=0.0034), whereas the number of segments
showing obstructive plaques was lower, and the number
of segments with no or minimal lesion was not different
between the two groups (Table 2). Per plaque analysis, the
noncalcified plaques weremore frequently observed in group
Bpatientswith respect to groupApatients, without difference
in calcified or partially calcified plaques (Table 2). In group
A patients, CTA, respectively, demonstrated 13 (24%), 10
(22.7%), and 5 (62.5%) patients with O-CAD, among patients
whose results showed negative, inconclusive, and positive
functional tests (see Table 3). After examining the results
of CTA, the planned investigations changed mainly due to
the exclusion or identification of O-CAD. Specifically, among
group A patients, the 42.5% identified with no O-CAD
had ICA cancelled, and 31.1% with normal/minimal CAD
did not undergo other tests. Among group B patients, the
63.7% with no O-CAD avoided functional testing, and the
27.4% with normal/minimal CAD did not undergo other
tests. The 26.4% and the 8.8% of patients with O-CAD
among groups A and B, respectively, underwent ICA directly
without additional noninvasive functional tests, considering
the availability in catheterization lab of IVUS and FFR in
case of the persistence of uncertainty of the significance of
coronary stenosis after ICA evaluation. Overall, in patients
presenting with O-CAD by CTA (n=37), ICA confirmed
obstructive CAD in 92% (23/25) of cases. In 2 patients, the
intravascular ultrasound did not confirm a case of O-CAD
detected by CTA, demonstrating an overestimation of the
degree of the coronary stenosis (sensitivity 100%, specificity
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Figure 2: A: relationship between number of diseased coronary vessels and coronary risk factor (RF) ≥2 vs. RF 0-1 (P=0.0035). B: relationship
between number of diseased coronary vessels and pretest probability low vs. intermediate and high (P=0.0199).
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Figure 3: A: relationship between percentage of patients with proximal plaques and coronary risk factor (RF) ≥2 vs. RF 0-1 (P=0.0009). B:
relationship between percentage of patients with proximal plaques and pretest probability low vs. intermediate and high (P=0.0173).
60%, positive predictive value 92% [95% CI 75.3 to 97.77],
negative predictive value 100% [95%CI 43.85 to 99.99%], and
accuracy 92.85%). In the remaining 12 patients, ICA was not
performed due to plaques located in distal part of coronary
vessel in 5 patients (3 from group A) and in minor branches
in 7 patients (3 from group A). These patients with stable O-
CAD were treated with optimal medical therapy. In case of
the persistence of symptoms despitemedical treatment, a PCI
was performed 3 months after CTA, after the demonstration
of large amount of myocardial ischemia (n=3) or positive
fractional flow reserve (n=1).
3.1. Cost Analysis. The cost analysis revealed that the average
diagnostic cost per patient for patients in group A was 324.42
euros (95% CI: 310.34-338.51); for patients in group B, it was
206 euros (P<0.0001). Thus, the diagnostic cost-savings was
a difference of 118.42 euros while using CTA as a first-line
investigative strategy, as compared to the standard strategy.
3.2. High-Pitch vs. Standard CTA. The patient heart rate
was lower in those who underwent high-pitch CTA in
comparison to those who underwent standard CTA (55±4
bpm vs. 67±7 bpm, P<0.001).Themean cumulative radiation
exposure was also lower in patients receiving high-pitch
vs. standard CTA mode (1.48±1.36 mSv vs. 8.10±3.14 mSv,
P<0.001). The agreement between the two observers in
assessing image quality was excellent, with a kappa result of
0.93.The number of segments exhibiting coronary vessels not
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Table 3: Functional test and CTA results of Group A and Group B patients.
Functional test results CTA results
Obstructive CAD No obstructive CAD Minimal lesions/no CAD
Group A (n = 106)
All, n (%) 28 (26.4%) 45 (42.5%) 33 (31.1%)
Negative, n (%) 54 (50.9%) 13 (24.1%) 23 (42.6%) 18 (33.3%)
Positive, n (%) 8 (7.5%) 5 (62.5%) 1 (12.5%) 2 (25.0%)
Inconclusive, n (%) 44 (41.5%) 10 (22.7%) 21 (47.7%) 13 (29.5%)
Group B (n = 102)
All, n (%) 9 (8.8%) 65 (63.7%) 28 (27.4%)
Negative, n (%) - - - -
Positive, n (%) - - - -
Inconclusive, n (%) - - - -
Data are presented as number (percentage).
able to be evaluated (quality score=4) was low and similar
in both high-pitch and standard CTA mode: 1.2% vs. 1.04%
(P=0.634), respectively. Following CTA, an allergic reaction
to the contrast medium agent occurred in 1 patient, who was
successfully treated with cortisone and antihistamine agents.
3.3. Follow-Up. Throughout a median 3-year follow-up
(group A 36.3±11.2 months and group B 36.7±11.4 months,
P=0.798), death and myocardial infarction did not occur
in any of the patients with no O-CAD and cancelled ICA
(from group A) nor in those with a cancelled functional test
(from group B).The unplanned evaluations in the emergency
department included two cases of palpitations, one for each
group, and two cases of acute chest pain, one for each group;
both were discharged from the hospital uneventfully.
4. Discussion
Currently, a great debate occurs about the functional and
anatomic diagnostic evaluation ofCAD inpatients presenting
with new onset chest pain. After the publication of recent
studies [4–6], the NICE guidelines recommended the use of
coronary CTA as a first-line diagnostic test evaluation for
all patients presenting with new onset chest pain suspected
for CAD [7]. Our findings confirm that in clinical practice
the use of coronary CTA, given its strong negative predictive
value [12], allows us to avoid unnecessary functional tests or
a more expensive and potentially harmful ICA in patients
showing normal coronary arteries or no O-CAD. Undoubt-
edly, CTA increased the identification of both obstructive and
no O-CAD. While currently there is no clear guidance on
how to manage the case of no O-CAD, the most common
pattern of atherosclerosis observed in new onset chest pain
patients, there is growing evidence of the beneficial effects
of statin therapy [13]. Not surprisingly, in our registry, the
burden of diseased vessels and the rate of proximal plaques
by CTA increased with the presence of more than two
coronary risk factors, as well as with the increase of tertile
risk factor among all patients at intermediate-risk profile.
Categorizing CAD on the basis of stenosis severity alone
fails to account for the continuum of risk associated with no
obstructive atherosclerotic plaques [14]. It will be interesting
to see whether the identification of vulnerable plaques by
CTA will improve the risk stratification of future cardiac
events, beyond the risk profile of patients at presentation
[15]. In symptomatic patients with a suspicion of CAD, the
recurrence of chest pain is frequent and usually patients
undergo an additional functional test, due to the uncertainty
of CAD presence, or undergo ICA directly, according to
the behavior of the attending physician and the availability
of local facilities and expertise. Thus, not surprisingly, in
the USA [16], as well as in a European study [17], 40% of
ICA patients present no O-CAD, contributing to an inap-
propriate and unjustified consumption of financial resources.
Currently, in patients with stable CAD, the rate of occurrence
of events during a follow-up appears to be reduced, in
comparison with that reported in Courage ERA [18] and,
in a more recent study [3], it was as low as 1.5%. Moreover,
for symptomatic patients with normal coronary arteries, no
additional evaluation test is necessary until 5 years fromCTA
according to the large CONFIRM study [19]. In our registry,
no events were reported during the median 3-year follow-
up for patients showing normal coronary arteries as well as
no O-CAD. More recently, the 5-year clinical outcome of
SCOT-HEART trial [20] showed that the use of CTA versus
standard care alone is associated with a lower subsequent
risk of death from CAD or nonfatal myocardial infarction
(2.3% vs. 3.9%; HR 0.59).This benefit was achieved without a
greater long-term use of ICA and coronary revascularization
in the CTA group. According to the design of the study, the
SCOT-HEART trial encouraged the secondary prevention
strategy, i.e., statin agents, in patients with no O-CAD. This
strategy may be very important, considering that nearly
half of subsequent myocardial infarctions occurred among
patients with no O-CAD. Finally, in patients showing O-
CAD involving small coronary vessels or marginal branches,
we avoided performing ICA and angioplasty. These patients
remained uneventful throughout the follow-up. In fact, in
this setting, the advantage of angioplasty in comparison to
optimalmedical therapy remains to be demonstrated [21, 22].
Thus, it is conceivable that, in the near future, the role of CTA
as a prevention strategy could be expanded, thus avoiding
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invasive evaluation for patients with minimal or no O-
CAD, as well as promoting preventive therapies, and finally,
improving the appropriateness of ICA—avoiding coronary
angioplasty in small vessels or minor branches showing low-
risk obstructive plaques.
4.1. Radiation Dose. The radiation dose remains the main
concern regarding the use of CTA in clinical practice, due
to the cancer risk it poses. According to ALARA dogma
[11], all techniques should be improved in order to reduce
the effective radiation dose. Our findings demonstrated a 6-
fold reduction of radiation dose by using high-pitch mode
with respect to standard CTA mode. However, the feasibility
of the high-pitch CTA mode depends on the patient heart
rate. Despite the aggressive heart rate strategy control with
beta-blocker/ivabradine adopted in our centre, the high-
pitch CTA mode was feasible in only half of the patients,
underlying the difficulty in implementing the high-pitchCTA
mode in clinical practice. It is important to note, however,
that the radiation dose for nuclear stress testing was even
higher, with an average level of 14 mSv, as noted in the
literature, in comparison to that of the standard CTA scan
[23]. In addition, the diagnostic certainty of chest pain
may be lost, and the ICA examination may be necessary
in the case of doubts raised by the results of functional
tests. Finally, the lessening of the radiation dose obtained
by this technique may affect the quality of the imaging.
However, we note that in our registry, the reduction of
effective radiation exposure obtained by high-pitch CTA
mode did not have a significant impact on the imaging
quality.
4.2. Limitations. This studywas a single-center, observational
registry with inherent limitations. First, due to the small
sample size, caution is needed in the interpretation of the
results. Second, the appropriateness of extrapolation of our
findings to other centers will depend on the comparability
of the clinical setting in terms of current diagnostic care,
available technology, cost-accounting systems, and therapeu-
tic management attitudes. Third, for the evaluation of outpa-
tients with new onset chest pain, the combination of both
anatomic and functional data could be the best diagnostic
strategy [3]; however, the fractional flow reserve-CTA and
the fusion/hybrid imaging is not available in our centre.
Finally, in the present registry, the diagnostic CTA strategy
is deemed to be cost-saving; however, the cost-effectiveness
of CTA and the downstream health-care resource utilization
both need to be evaluated in larger studies, though the NICE
cost utility analysis of CTA appears favorable [7]. In addition,
an important limitation of this registry is represented by
the cost analysis performed by considering only the diag-
nostic workflow tests, whereas the cost saving related to the
downstream ICA cancellation and avoided functional tests,
and the additional costs related to the management of O-
CAD were not factored into the evaluation. Despite these
limitations, we included outpatients who were representative
of those referred to the cardiology clinic for assessment of
suspected angina due to CAD. A similar rate of O-CAD was
found in our chest pain population as in the larger SCOT-
HEART study (17.8% vs. 24%), and a similar majority of
our patients underwent an exercise test as those reported
in the SCOT-HEART study (96% vs. 85%), confirming this
overall picture. In our study, 42% of the exercise tests were
inconclusive and 24% of patients with negative stress tests
had obstructive CAD. Only 62.5% of positive stress tests
had obstructive CAD, confirming the moderate diagnostic
value of the exercise test. Yet, considering the well-known
overestimation of the prevalence of O-CAD based on the
risk models [19] due to the low rate of O-CAD in real
world populations with stable chest pain symptoms, CTA
could be an efficient first-line test [4, 5, 7]. Thus, one should
realize that in real-world setting, the use of CTA scan
as a first-line diagnostic strategy for outpatients with new
onset chest pain may be both feasible, safe, and cost-saving.
However, a forward-looking economic investment strategy is
necessary for the implementation and integration of CTA in
the diagnostic workup for chest pain in the clinical practice
[24].
4.3. Conclusions. Our registry confirms that in new onset
chest pain patients no O-CAD was the pattern of atheroscle-
rosis most commonly detected by the CTA, as first- or
second-line investigation test. Implementation of CTA for
clinical decision-making may influence the downstream
diagnostic workflow of patients in real-world setting, leading
us to safely avoid unnecessary ICA or additional functional
tests. Although CTA appears to be cost-saving, the cost-
effectiveness of CTA integration in the diagnostic workflow
for suspicion of CAD in real world remains to be demon-
strated in larger studies.
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